Phys.org on MSN11d
Revolutionizing Antibody Discovery: MIT’s AI BreakthroughWith this model, researchers may be able to discover antibody drugs capable of targeting a wide range of infectious diseases.
Transforming the landscape of drug discovery with next-gen capabilities in obesity research, small molecule and antibody design, antibody-drug conjugate development, and interactive AI AlpaMeld Logo ...
UCB, a global biopharmaceutical company, and XtalPi, a global leader in AI drug discovery, today announced a license ...
AMD's technology will also be used to boost Absci's drug discovery workload, including the company's de novo antibody design ...
These include Bispecific Antibodies and Antibody Drug Conjugate (ADC) therapies ... this technology now in clinical ...
ScienceAlert on MSN2d
Parkinson's Discovery Suggests We Could Already Have an FDA-Approved TreatmentResearchers have discovered how a cell surface protein called Aplp1 can play a role in spreading material responsible for ...
The market is projected to grow from $11B in 2024 to $40B by 2030, driven by both conventional bispecifics and advancements such as antibody-drug and ... Antibody Discovery process can align ...
Absci recently received a $20 million PIPE investment from AMD that improves its runway and R&D platform with AI. See why I ...
General Manager and CEO of Junshi Biosciences, Dr. Jianjun ZOU, said, "Toripalimab has made significant strides in its ...
MELBOURNE, Australia and INDIANAPOLIS, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces it has entered into an asset purchase ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback